Background Patients with severe aortic stenosis (AS) are at high risk of mortality, regardless of symptom status. Despite ...
Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...
Medera Inc. ('Medera'), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...
Three new performance measures and six new quality measures are included as part of updated "Clinical Performance and Quality Measures for Adults With Heart Failure" released by the ACC and the ...
Good afternoon, everyone. Welcome to our Piper Sandler Healthcare Conference. My name is Yas Rahimi. I'm a senior biotech analyst at Piper Sandler. So thrilled to have the team from Edgewise ...
Accurate segmentation and landmark detection are essential for medical image analysis. However, existing methods often struggle with generalization and robustness, particularly under sparse annotation ...
Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life THE WOODLANDS, Texas, Nov. 08, 2025 ...
Background: First-phase ejection fraction (EF1) has been recently demonstrated to sensitively detect early cardiac systolic dysfunction. However, the value of EF1 in predicting myocardial fibrosis (MF ...
Background: In heart failure (HF) with reduced ejection fraction (HFrEF), ventricular secondary mitral regurgitation (V-sMR) leads to progressive impairment of right ventricular (RV) function and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback